Innospec (IOSP) to Release Quarterly Earnings on Tuesday

Innospec (NASDAQ:IOSPGet Rating) is scheduled to release its earnings data after the market closes on Tuesday, May 3rd. Analysts expect Innospec to post earnings of $1.18 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Innospec (NASDAQ:IOSPGet Rating) last issued its earnings results on Tuesday, February 15th. The specialty chemicals company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.01 by $0.29. The company had revenue of $413.20 million for the quarter, compared to analyst estimates of $378.60 million. Innospec had a net margin of 6.28% and a return on equity of 12.06%. During the same period in the previous year, the firm earned $1.27 EPS. On average, analysts expect Innospec to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Shares of IOSP opened at $94.64 on Tuesday. Innospec has a 52-week low of $81.00 and a 52-week high of $107.14. The company has a 50-day simple moving average of $94.44 and a 200-day simple moving average of $92.04. The company has a market capitalization of $2.37 billion, a PE ratio of 25.30 and a beta of 1.30.

A number of research analysts have issued reports on the stock. Zacks Investment Research cut shares of Innospec from a “buy” rating to a “hold” rating in a report on Thursday, March 10th. Seaport Res Ptn reaffirmed a “neutral” rating on shares of Innospec in a research note on Wednesday, March 30th. Finally, StockNews.com upgraded Innospec from a “buy” rating to a “strong-buy” rating in a research report on Monday. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $108.00.

In other Innospec news, CEO Patrick Williams sold 11,448 shares of the firm’s stock in a transaction on Friday, February 25th. The stock was sold at an average price of $96.77, for a total transaction of $1,107,822.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ian Cleminson sold 2,035 shares of the company’s stock in a transaction on Friday, February 25th. The shares were sold at an average price of $96.78, for a total value of $196,947.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,713 shares of company stock valued at $1,521,521. 1.52% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Innospec by 9.5% in the fourth quarter. BlackRock Inc. now owns 4,268,047 shares of the specialty chemicals company’s stock valued at $385,574,000 after buying an additional 370,154 shares during the last quarter. State Street Corp grew its stake in Innospec by 6.3% in the 4th quarter. State Street Corp now owns 859,151 shares of the specialty chemicals company’s stock worth $77,616,000 after acquiring an additional 50,729 shares during the period. Goldman Sachs Group Inc. raised its holdings in Innospec by 25.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 241,504 shares of the specialty chemicals company’s stock valued at $21,817,000 after acquiring an additional 49,638 shares during the last quarter. Morgan Stanley lifted its stake in shares of Innospec by 92.8% during the 2nd quarter. Morgan Stanley now owns 119,379 shares of the specialty chemicals company’s stock worth $10,818,000 after purchasing an additional 57,445 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of Innospec by 3.6% during the fourth quarter. Parametric Portfolio Associates LLC now owns 84,793 shares of the specialty chemicals company’s stock worth $7,660,000 after purchasing an additional 2,934 shares during the last quarter. Institutional investors and hedge funds own 98.99% of the company’s stock.

Innospec Company Profile (Get Rating)

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in various fuels.

Featured Articles

Earnings History for Innospec (NASDAQ:IOSP)

Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.